Topped up quite a bit in the gap also. PLS outperforming this today which is just ridiculous as I can't see any coordinate in which their report outshines AKE during this quarter. Hurry up Jame Bay ffs LOL!!
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%